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Bone metastases are a common manifestation of malignancy, and external beam radiotherapy (EBRT)
effectively and safely palliates the pain caused by this clinical circumstance. The myriad of EBRT dosing
schemes and complexities involved with coordinating radiotherapy with other interventions necessi-
tated the need for bone metastases treatment guidelines. Here we compare and contrast the bone
metastases radiotherapy treatment guidelines recently published by the American Society for Radiation
Oncology (ASTRO) and the American College of Radiology (ACR). These evaluations acknowledge current
controversies in treatment approaches, they evaluate the nuances of ASTRO and ACR task force decision-
making regarding standard approaches to care, and they project the upcoming research results that may
clarify approaches to palliative radiotherapy for bone metastases. The results of these two dedicated
radiotherapy guidelines are compared to the brief mentions of radiotherapy for bone metastases in the
National Comprehensive Cancer Network (NCCN) guidelines. Finally, the paper describes how treatment
guidelines may inﬂuence patterns of care and reimbursement by their use as quality measures by groups
such as the National Quality Forum (NQF).
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Bone metastases as a clinical problem
Many cancers metastasize to bone, with the most common
sites of origin of primary disease being breast, lung, thyroid,
kidney, prostate, and malignant melanoma of the skin. The
presence of tumor in the bone can lead to local symptoms
such as pain, spinal cord compression, and pathologic fracture,
as well as systemic effects caused by hypercalcemia. The work-up
and treatment of bone metastases requires input and interven-
tions from many medical disciplines, including radiologists,
orthopedic surgeons or neurosurgeons, radiation oncologists,
medical oncologists, pain medicine specialists, physical medicine
and rehabilitation physicians, and palliative care professionals.
The delivery of radiation therapy to these patients requires
communication and coordination of scheduling with these other
specialists. Furthermore, the aggressiveness of treatment must
take into account patient factors such as performance status and
co-morbidities, tumor factors such as stage and histology, and
treatment factors such as sequencing and risks of concurrent
therapy [1–3].. This is an open access article un
: þ1 419 427 0212.2. Radiotherapy for bone metastases
As a palliative intervention, radiotherapy is effective and
efﬁcient at treating painful bone metastases, and the side effects
associated with its use are manageable and usually self-limiting
in nature. Between 50% and 80% of patients gain at least partial
relief of their pain following external beam radiotherapy (EBRT),
and complete relief may be seen in up to one-third [4]. External
beam radiotherapy may be delivered to the same anatomic site
of affected bone in the case of recurrent pain. Technological
advances have created interest in the possibility that highly
conformal therapies may improve either the rates of pain relief
or the duration of the results of treatment, especially in cases of
tumors located in bones of the spine. These treatments are
termed stereotactic body radiation therapy (SBRT), or stereotactic
ablative body radiotherapy (SABR), and are given by machines
that deliver intensity modulated radiation therapy (IMRT), Cyber-
knife therapy, Tomotherapy, or proton therapy. Patients with
spinal cord compression may receive EBRT primarily or as an
adjuvant treatment after surgical decompression. Kyphoplasty or
vertebroplasty may be used in cases where there is no spinal cord
compression, but where spinal instability is noted and contributes
to metastatic bone pain. Furthermore, injectable radiopharma-
ceuticals such as Strontium 89, Samarium 153, and Radium
223 may be delivered to patients with widespread tumors whose
histologies are osteoblastic and therefore easily visualized onder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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inhibiting agents may be considered concurrently or sequentially
with EBRT.3. Emergence of radiotherapy guidelines
The driving forces behind the emergence of radiotherapy
guidelines include a desire to maximize pain relief and functional
capabilities of an individual patient while minimizing the risks of
treatment toxicity. The treatment guidelines are also meant to
serve as a means by which to guarantee a minimum standard of
care across geographic locales and different practice settings. And,
given some areas of incomplete data regarding the proper choice
for treatment, one goal of the guidelines is to acknowledge and
address the controversies that arise due to that lack of complete
data. From a societal standpoint, the guidelines provide a means
to assess the best practice patterns as developed countries face an
increased number of cancer patients with resource constraints
and many developing countries struggle with throughput limita-
tions on antiquated machinery.4. International Consensus Conference Bone Metastases
treatment recommendations
The prelude to many of the questions posed and answers
offered by the existing bone metastases treatment guidelines was
contained in previous International Consensus Conference Bone
Metastases treatment recommendation publications. The First
International Consensus Workshop on radiation in the treatment
of metastatic and locally advanced cancer convened in the United
States in 1990 [5]. A group of 116 experts evaluated the available
palliative radiotherapy data and generated consensus statements
for the treatment of bone metastases, amongst other clinical
circumstances. Those statements included treatment pathway
recommendations, an assessment of international variations in
treatment approach, the effects of successful treatment on quality
of life, and the role of economic factors in the management of this
patient group. The Second Workshop on Palliative Radiotherapy
and Symptom Control convened in London in 2000 and conﬁrmed
the efﬁcacy of EBRT in controlling pain caused by metastatic bone
disease [6]. That group reviewed the efﬁcacy of a single 8 Gy
fraction, they better deﬁned the proper use of radiopharmaceu-
ticals for patients with widespread painful disease, and they
recommended the standardization of response measurement
that led to the development of the International Consensus on
Palliative Radiotherapy Endpoints document. Finally, the Third
International Consensus Conference Workshop was held in con-
junction with the ASTRO meeting with representatives from
ASTRO, European Society for Therapeutic Radiology and Oncology
(ESTRO), Trans-Tasman Radiation Oncology Group (TROG) and
Canadian Association of Radiation Oncology (CARO) in San Diego,
California, in 2010 and called for both formal treatment guide-
lines and a means by which to enhance palliative radiotherapy
efforts in developing countries around the world.5. Formal radiotherapy bone metastases treatment guidelines
The American College of Radiology (ACR) Appropriateness
Criteria format employs common clinical circumstances, or ‘‘var-
iants’’, which serve as a means for an expert panel to vote upon
the most appropriate interventions for that scenario (Table 1). The
panel members collectively base their assessments upon the
results of published literature, though the clinical experience of
those experts may inﬂuence their decision-making, especiallyin situations where the available data set is incomplete. The bone
metastases treatment panel consists of representatives from
radiation oncology, nuclear medicine, orthopedic surgery, and
medical oncology. The clinical case scenarios allow for recom-
mendations about the best combination of interventions as well
as an assessment of the proper radiotherapy treatment set-ups
and fractionation schemes. While previous ACR publications
have included all types of bone metastases situations in a single
manuscript, the increasing complexity of treatment of spine
metastases and spinal cord compression led to the division of
‘‘spine’’ and ‘‘non-spine’’ topics. The most recent update of the
non-spine topic has just been published, while the spine topic
update is still being formulated [7].
The ﬁrst variant in the non-spine topic describes a patient with
an excellent performance status, a favorable life expectancy, and
an asymptomatic femur lesion which does not pose an obvious
risk for pathologic fracture. While the authors acknowledge that
research has begun to determine whether patients with bone-
only metastatic disease and otherwise favorable ﬁndings may be
treated aggressively, they stop short of endorsing curative-intent
therapy for patients with ‘‘oligometastases’’ because the available
data do not yet prove the usefulness of such an approach [8].
Their recommendations therefore call for an osteoclast inhibitor
and a hormone blocking agent, with radiotherapy reserved for
an oligometastatic treatment trial. The results of ongoing research
may well come to indicate that patients in this most favor-
able clinical circumstance of metastatic disease should be treated
more aggressively than others with less favorable prognostic
indicators.
The second variant describes a patient with a good perfor-
mance status who has a painful lesion in a weight-bearing bone.
The task force deﬁned the need for quickly establishing a pain
medicine regimen while concurrently consulting an orthopedic
surgeon to assess the need for surgical pinning to prevent
pathologic fracture [9–11]. Given a low risk of fracture deter-
mined by the surgeon, the team recommended external beam
radiotherapy (EBRT) based upon CT, ﬂuoroscopic, or clinical
simulation, with radiation delivery through anterior and posterior
ﬁelds sparing a skin strip to minimize the risk of long term
lymphedema of the extremity. While the panel detailed the pain
relief equivalency between a single 8 Gy fraction and multi-
fraction schedules, they pointed out the data which suggests
that the use of fractionated regimens might minimize the risk of
subsequent pathologic fracture in this setting [12]. The group
essentially declared that pain relief equivalency has been con-
clusively determined for either single fraction or multi-fraction
regimens, obviating the need for further research to examine
that question. Finally, the existence of a fairly signiﬁcant tumor
burden in that patient led to recommendations for considering
systemic chemotherapy and osteoclast inhibitors.
In the third variant, the patient has suffered a pathologic
fracture from a lytic metastasis in a weight-bearing bone that
required surgical stabilization. The panel recommended post-
operative radiotherapy with 30 Gy in 10 fractions planned by
CT, ﬂuoroscopic or clinical simulation, with anterior and posterior
opposed ﬁelds and a skin strip spared to once again minimize
the risk of long term lymphedema. The vignette is valuable in its
ability to highlight the need for orthopedic consultation to assess
and provide surgical stabilization as well as the need for com-
munication for the patient to receive the necessary post-operative
adjuvant radiotherapy. Given a good performance status and
signiﬁcant tumor burden, recommendations were made for con-
siderations of systemic chemotherapy, hormonal ablation treat-
ment, and an osteoclast inhibitor.
The patient in variant number 4 has previously received
palliative radiotherapy for a site of painful bony disease with
Table 1
Summary of recommendations regarding radiotherapy for bone metastases in the most recent guidelines from the American College of Radiology, the American Society for
Radiation Therapy, and the National Comprehensive Cancer Network.
American College of Radiology Appropriateness Criteria Non-Spine Bone Metastases [7]
Details of variant Radiotherapy recommendations
#1—Excellent PS, favorable LE, asymptomatic femur lesion, minimal risk of
pathologic fracture
RT only on trial
#2—Good PS, painful lesion in weight-bearing bone, some risk of pathologic
fracture
Orthopedic consult, RT alone or post-op depending upon need for surgery
#3—Pathologic fracture in weight-bearing bone, status post surgical pinning
procedure
Post-op RT to 30 Gy in 10 fractions, sparing a skin strip to minimize edema risk
#4—Recurrent pain following previous RT to same site of skeleton Consider re-treatment RT, respect normal tissue tolerance, consider treatment
protocol
#5—Short LE, visceral metastases, single site of painful bone metastasis RT with a single 8 Gy fraction to minimize patient discomfort and travel time
PS¼performance status, LE¼ life expectancy, RT¼radiotherapy
American Society for Radiation Oncology Bone Metastases Guidelines [2]
Clinical question Conclusions
#1—When is single fraction radiotherapy appropriate? Single fraction radiotherapy is a reasonable option for all patients with painful bone
metastases
#2—May spine lesions be treated with single fraction therapy? Single fraction therapy is safe, effective, and convenient for patients with painful
spine metastases
#3—Should long-term side effect risks limit the use of single fraction therapy? Long term side effect risks are not measurably higher in patients treated with single
fraction radiotherapy
#4—When should patients receive re-treatment with radiation to peripheral
bone metastases?
Re-treatment may be effective and safe, though the paucity of published data
suggests a need to accrue patients to open trials
#5—When should patients receive re-treatment with radiation to spine lesions
causing recurrent pain?
Re-treatment to painful lesions of the spine requires close attention to published data
regarding spinal cord tolerance; accrual to clinical trials is recommended
#6—What role does highly conformal radiotherapy play in the primary
treatment of painful bone metastasis?
Stereotactic body radiation therapy (SBRT) holds promise for the treatment of spine
metastases, though data regarding its proper uses is still accruing
#7—When should SBRT be considered for re-treatment of painful spine
lesions?
Spinal cord-sparing SBRT may be strongly preferable for the re-treatment of painful
spine metastases, though data regarding its proper uses is still accruing
#8—Might radiotherapy be omitted in patients who undergo surgery or who
receive radionuclides, bisphosphonates or kyphoplasty/vertebroplasty?
Radiotherapy is appropriate and necessary for most patients who undergo surgery or
who receive other treatments for painful bone metastases
National Comprehensive Cancer Network Bone Metastases Treatment Recommendations [38–47]
Clinical disease site Radiotherapy recommendations
Non-small cell lung cancer 20–30 Gy in 5–10 fractions for metastases with soft tissue mass
8–30 Gy in 1–10 fractions for metastases without soft tissue mass
Small cell lung cancer Radiotherapy can provide excellent palliation of painful bone metastases
Kidney cancer Consider radiotherapy with the goal of long-term progression free survival in patients
with single bone metastasis and controlled primary disease
Multiple myeloma ‘‘Low dose’’ radiotherapy recommended to 10–30 Gy for bone pain, impending
pathologic fracture, or impending spinal cord compression
Prostate cancer 8 Gy in a single fraction to non-spine lesions
fractionated radiotherapy for spine lesions
radiopharmaceuticals for widespread metastases
Thyroid cancer Radiotherapy for painful bone metastases, without any suggestion of proper dose
fractionation schema
Breast cancer No mention of radiotherapy for painful bone metastases
Adult cancer pain guidelines Radiotherapy should be considered for painful lesions which are likely to respond to
antineoplastic therapies
Palliative care guidelines No mention of radiotherapy for painful bone metastases
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panel was tasked with evaluating the safety and efﬁcacy of EBRT
re-treatment to the same painful site. The panel described the
available re-treatment data as being of low quality because it was
mostly retrospective, single-institutional, and dated [13–18].
Given those limitations, the group recommended caution when
treating volumes containing normal tissue structures which
might suffer side effects from the combined palliative doses.
The brachial plexus was found to be one normal tissue at risk in
this particular case, and the team also reminded the reader to re-
evaluate the affected long bone for risk of pathologic fracture
before offering re-irradiation. The panel therefore recommended
treatment planned by CT, ﬂuoroscopic, or clinical simulation, with
anterior and posterior opposed ﬁelds sparing a skin strip to
minimize the risk for upper extremity edema. Given limited data
regarding the best dose to use in this setting, the panel recom-
mended placing the patient on an available re-treatment protocol
[19]. When completed, the results of that trial will need to serve
as a template for the appropriateness of re-treatment to the same
painful site, given the lack of prospective data available at thistime. While the use of systemic chemotherapy was not thought to
be wholly inappropriate, the patient’s poor performance status
and prognosis led the group to suggest that the patient be seen
by a palliative care team and be given the option to choose
hospice care.
The ﬁnal variant deals with a patient who has a poor prognosis
due to visceral metastases and who suffers from a single site of
painful bone disease. The purpose of the case was to evaluate the
panel’s views of supportive care with analgesic medications plus
or minus EBRT. The group did recommend EBRT for the patient,
but they were speciﬁc in their belief that the dose should be
limited to a single 8 Gy fraction in an effort to decrease time spent
in treatment and discomfort from being transferred on and off the
treatment table [20]. The likelihood of an increased need for re-
treatment to the same site in this patient is diminished by his
short expected lifespan. It was recommended that CT, ﬂuoro-
scopic, or clinical simulation may be used while preparing
treatment through AP and PA directions while sparing a skin
strip. Anti-inﬂammatory medicines were described as the best
method to manage any temporary ﬂare reaction that might occur
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was thought to be a reasonable directive, either before or after the
completion of the single fraction EBRT dosing.
In its text, the ACR Appropriateness Criteria Bone Metastases
Group suggested several general statements applicable to most or
all ﬁve variants. First, EBRT was re-deﬁned as an effective means
to palliate the pain caused by metastatic bone disease, with rates
of relief of 50%–80% and equivalence for fractionation schemes
including 30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in
5 fractions, and a single 8 Gy fraction [4,22,23]. The preferred
treatment set-up and prescription points should follow those
deﬁned in the International Consensus on Palliative Radiotherapy
Endpoints [24]. The group determined that the use of highly
conformal therapy with intensity-modulated radiation therapy
(IMRT), stereotactic body radiation therapy (SBRT), or proton
therapy have not been proven for this subset of patients without
spine disease. Lastly, the need for concurrent pain medicine
dosing and palliative care was seen to be imperative, with hospice
admission not viewed as being mutually exclusive with the
delivery of palliative radiotherapy for bone pain.6. American Society for Radiation Oncology (ASTRO) bone
metastases guidelines
The American Society for Radiation Oncology (ASTRO) has only
recently begun creating clinical treatment guidelines, especially
when compared to the longstanding existence of the ACR Appro-
priateness Criteria. In 2009 the ASTRO Board of Directors tasked
the Health Services Research Committee to create bone metas-
tases treatment guidelines. The ASTRO group consisted of a
neurosurgeon and palliative medicine expert as well as radiation
oncologists from academic, private practice, and residency set-
tings. The group was asked to create guidelines that were
applicable to patients as well as healthcare providers, with one
of the main themes being the integration of radiotherapy with
other treatment modalities useful in the care of patients with
painful bone metastases. The original literature search covered
the most recent ten years of citations in the National Library of
Medicine’s PubMed database and yielded over 4000 publications.
Within that group of papers were found 25 randomized clinical
trials, 20 prospective single-arm studies, and 4 meta-analyses or
systematic reviews. Given the complexity of the clinical situations
involved in the care of these patients, the task force was divided
into subgroups to concentrate on those issues that ﬁt each
individual’s own expertise. The results of the subgroups’ work
were subsequently presented to the entire group, made available
online for public comment, and approved by the ASTRO board of
directors prior to publication [2].
The format of the ASTRO guidelines was based upon the task
force answers to several questions posed by the board of direc-
tors. The ﬁrst several questions dealt with the most appropriate
external beam radiation therapy (EBRT) fractionation scheme to
use for the treatment of painful bone metastases. While the rates
of pain relief following EBRT appear to be similar across a wide
array of dose fractionation schemes, one recent worldwide survey
revealing that more than 101 fractionation schemes are used for
this one clinical circumstance [25]. The ﬁrst goal of the task force
was therefore to narrow the list of acceptable fractionation
schemes to those which have been sufﬁciently studied in ade-
quately-powered trials. Similar to the ACR group, they documen-
ted that several prospective, randomized trials have evaluated
different dose-fractionation schedules, with the results suggesting
equivalence in pain relief after schedules including 30 Gy in 10
fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, and a single
8 Gy fraction [2,4]. The advantage of single fraction radiotherapywas seen to be increased convenience and decreased expense for
the patient and their caregivers, while multiple fraction therapy
was advantageous because it is associated with a lower incidence
of re-treatment to the same painful site than in single fraction
treatment (8% versus 20%, respectively) [4]. In answer to concerns
raised about the safety of a single 8 Gy fraction to anatomic sites
historically considered to be sensitive to hypofractionated doses,
the task force evaluated the literature but could not ﬁnd any long
term side effect risks that should deter clinicians from using a
single dose to spine ﬁelds that contain the spinal cord or cauda
equina [26].
The re-treatment of metastatic bone disease causing recurrent
pain after an initial course of EBRT was seen to be feasible with a
reasonable rate of symptom relief [13–19]. In echoing the ACR
ﬁndings, the task force noted that the available data was derived
from studies where re-treatment was not the primary endpoint
studied, and that many of the descriptions of re-treatment were
based upon small numbers of patients. Additionally, the authors
cautioned that re-treatment may only be considered when taking
into account the normal tissue tolerance of structures included
in the treated volumes. The spinal cord and cauda equina were
speciﬁcally mentioned as structures whose tolerance to the
combined dosing must be taken into account when delivering a
second course of EBRT to the spine.
Given signiﬁcant interest in newer technologies amongst
radiation oncologists and neurosurgeons, the ASTRO task force
enthusiastically recognized the promise for improvements in care
with highly conformal therapy which includes all technologies
that can deliver higher doses to metastatic bone disease with a
steep dose gradient to spare adjacent normal structures. The team
focused their analysis on the potential beneﬁts of stereotactic
body radiation therapy (SBRT) for metastases in spine bones,
though they described that the available data for this intervention
has to this point been accrued in single institutional studies with
small numbers of patients whose responses have been measured
with novel treatment outcomes. As such, the task force suggested
that patients who receive SBRT should strongly be considered for
the available treatment protocols to better accrue data about
efﬁcacy and toxicity measures. The theoretical advantage of SBRT
for sparing spinal cord or cauda equina in the re-treatment of
recurrent, painful spine lesions was documented in much greater
detail than was true in the ACR Appropriateness Criteria [27–32].
In an attempt to clarify confusion regarding the use of radio-
therapy with other available interventions for painful metastatic
bone disease, the ASTRO task force clearly stated that EBRT is still
necessary in situations where patients receive surgery for spinal
cord compression or long bone stabilization, intravenous radio-
pharmaceuticals for widespread bone disease, osteoclast inhibi-
tors, or kyphoplasty or vertebroplasty for lytic lesions causing
spinal instability [33–36]. Surgery was only recommended for
patients with spinal cord compression who have a favorable
prognosis and sufﬁcient performance status to warrant the surgi-
cal risks and post-operative rehabilitation required for that degree
of intervention. Radiopharmaceuticals were deemed most appro-
priate in patients with widespread, painful osteoblastic metastases
that are apparent on a technetium-99 bone scan. While the use of
osteoclast inhibitors was seen as being a reasonable means by
which to palliate bone pain and promote re-ossiﬁcation, the task
force pointed out that there are no data to suggest that the
palliation of a single site of metastatic bone pain is superior with
osteoclast inhibitors plus EBRT versus EBRT alone. Finally, the task
force described the theoretical advantage of using kyphoplasty or
vertebroplasty for spinal instability caused by lytic metastases,
though they shared the belief that the data proving those assump-
tions was mostly derived from retrospective, single institutional
studies. In its conclusions, the ASTRO group suggested that future
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measurement of consistent variables as deﬁned by the Interna-
tional Consensus on Palliative Radiotherapy Endpoints while also
assessing functional domains and quality of life with validated
instruments such as the European Organization for Research and
Treatment of Cancer bone metastases quality-of-life questionnaire
[24,37].7. National Comprehensive Cancer Network (NCCN) and bone
metastases treatment recommendations
The National Comprehensive Cancer Network is made up of
experts from cancer centers of excellence around the United
States who designate representatives to committees that evaluate
data and provide treatment options for most common cancers
[38]. While there is no speciﬁc NCCN group designated to
evaluate the use of radiotherapy for bone metastases, the topic
is dealt with to varying degrees in the publications which deal
with primary diagnoses that are most likely to metastasize to
bone. The NCCN Guidelines also include a wider variety of author
specialty types for each clinical site than do the ACR and ASTRO
guidelines. Furthermore, while radiation oncologists make up the
majority of panel members on the ACR and ASTRO committees,
radiation oncologists generally make up a distinct minority, or are
a singular member, of the NCCN committees. As such, the NCCN
guideline recommendations regarding radiotherapy for bone
metastases are likely to result from less vigorous conversations
and voting criteria than might be true for those offered by the ACR
and ASTRO groups.
The authors of the NCCN non-small cell lung cancer guidelines
provide the most guidance about radiotherapy dosing for painful
bone metastases of any of the primary sites evaluated [39]. Bone
metastases due to non-small cell lung cancer are separated into
those ‘‘with soft tissue mass’’ versus those ‘‘without soft tissue
mass’’, with recommendations for 20–30 Gy in 5–10 fractions for
the former circumstance and 8–30 Gy in 1–10 fractions for the
latter. The small cell lung cancer guidelines go so far as to only
state that radiotherapy may provide excellent palliation of painful
bone lesions [40].
The kidney cancer guidelines hint at the notion of radiotherapy
for oligometastases, describing that long-term progression-free
survival has been noted in patients treated with radiotherapy for
a single bone metastases and controlled primary disease [41]. The
multiple myeloma guidelines recommend a ‘‘low dose’’ of radia-
tion therapy to between 10 and 30 Gy for bone pain, impending
pathologic fracture, or impending spinal cord compression. The
multiple myeloma authors caution clinicians to limit the volume
of irradiated ﬁelds to minimize the impact upon bone marrow
given the potential for additional chemotherapy or stem cell
harvest [42]. The prostate cancer guidelines suggest that a single
8 Gy dose should be used to treat painful bone disease, though in
contradistinction to the ACR and ASTRO guidelines, the NCCN
prostate cancer authors suggest that vertebral metastases should
receive a fractionated rather than single fraction dose. They also
offer a recommendation to use radiopharmaceuticals such as
strontium 89 or samarium 153 for widespread bony metastases
[43]. Similarly, the thyroid cancer group only mentions EBRT in
the setting of optimization of dosimetry for Iodine 131 for
treatment of painful bone metastases [44]. The NCCN adult cancer
pain guidelines suggest that radiotherapy be considered for
painful lesions which are ‘‘likely to respond to antineoplastic
therapies’’ [45]. Lastly, neither the breast cancer treatment guide-
lines nor the palliative care guidelines mention the use of radio-
therapy for painful bone disease [46,47].8. Implications of bone metastases guidelines
The publication of treatment guidelines may cause angst for
practitioners, given justiﬁable concerns that their decision-mak-
ing autonomy may be threatened by a need to pigeon-hole
clinical circumstances into pre-determined bins. It is certainly
true that third party payers and the Centers for Medicare and
Medicaid Services are interested in using guidelines to reward
literature-based patterns of care while questioning treatment
patterns that deviate sharply from those data. Still, the advan-
tages for the use of treatment guidelines include the provision of
a minimum standard of care and a delineation of those topics
which remain controversial enough to spur additional clinical
trials to reach consensus on outcomes. The interest for the bone
metastases treatment guidelines has been high, as is evidenced by
the fact that the ASTRO bone metastases treatment guidelines
were the most frequently downloaded articles in 2011 from the
International Journal of Radiation Oncology, Biology, and Physics
website [48]. One might foresee that ongoing interest in guide-
lines, in general, will spur more formal comparisons of formatting
and content that will aid in standardization across the publica-
tions from different societies. This convergence of guidelines
would most certainly decrease any discrepancies that currently
exist in recommendations offered by the task force groups.
The National Quality Forum (NQF) has been tasked with
measuring quality of care for speciﬁc clinical circumstances, to
analyze reports of how frequently those quality measures are
employed, and to provide guidance that improves patterns of care
[49]. The Affordable Care Act requires that the NQF provide
annual input to the Department of Health and Human Services
regarding a National Quality Strategy that provides measures and
tracks progress toward fulﬁlling those goals. The NQF Cancer
Endorsement 2011 group will evaluate EBRT dose fractionation
schemes for bone metastases treatment as its ﬁrst potential
measure of radiation oncology quality. If the NQF Cancer Com-
mittee and Board of Directors accept that measure, then the full
implications of bone metastases guidelines will be ascertained.
Finally, virtually all of the guidelines products provide a
disclaimer stating that the ultimate appropriateness of therapy
relies on the judgment of treating physician while taking into
account their experiences, the available clinical data, and the
speciﬁc circumstances of the patient who is undergoing that
care. Similarly, the details of the guidelines evaluated in this
manuscript are available online and should be read in detail
prior to making conclusive comments about their content and
recommendations.References
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